Budget impact analysis of medicines: estimated values versus real-world evidence and the implications

References

• De Lemos LLP, Guerra Júnior AA, Santos M, et al. The assessment for disinvestment of intramuscular interferon beta for relapsing-remitting multiple sclerosis in Brazil. Pharmacoeconomics. 2018 Feb;36(2):161–173.
   PubMed Web of Science ®Google Scholar
• Guerra-Júnior AA, Pires De Lemos LL, Godman B, et al. Health technology performance assessment: real-World Evidence for public healthcare sustainability. Int J Technol Assess Health Care. 2017 Jan;33(2):279–287.
   PubMed Web of Science ®Google Scholar
• Esandi ME, Gutiérrez-Ibarluzea I, Ibargoyen-Roteta N, et al. An evidence-based framework for identifying technologies of no or low-added value (NLVT). Int J Technol Assess Health Care. 2020;36(1):50–57.
   PubMed Web of Science ®Google Scholar
• IQVIA. The global use of medicine in 2019 and outlook to 2023 - forecasts and areas to watch. 2019. [cited 2019 Jan 4]. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/the-global-use-of-medicine-in-2019-and-outlook-to-2023.pdf
   Google Scholar
• IQVIA Institute for Human Data Science. Global oncology trends. 2018. [cited 2019 Jan 15]. Available from: https://www.iqvia.com/insights/the-iqvia-institute/reports/global-oncology-trends-2018
   Google Scholar
• Howard DH, Bach PB, Berndt ER, et al. Pricing in the market for anticancer drugs. J Econ Perspect. 2015;29(1):139–162.
   PubMed Web of Science ®Google Scholar
• Luzzatto L, Hyry HI, Schieppati A, et al. Second Workshop on Orphan Drugs participants. Outrageous prices of orphan drugs: a call for collaboration. Lancet. 2018 Sep 1;392(10149):791–794.
   PubMed Web of Science ®Google Scholar
• Cohen D. Cancer drugs: high price, uncertain value. BMJ. 2017 Oct 4;359: j4543.
   PubMed Web of Science ®Google Scholar
• Godman B, Wild C, Haycox A. Patent expiry and costs for anti-cancer medicines for clinical use. Generics and Biosimilars Initiative Journal. GaBI J. 2017;6(3):105–106.
   Google Scholar
• Godman B, Hill A, Simoens S, et al. Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert Rev Pharmacoecon Outcomes Res. 2021 Mar 11:1–14. Epub ahead of print. PMID: 33535841.
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Mauskopf JA, Augustovski F, et al. Principles of good practice for budget impact analysis II: report of the ISPOR Task Force on Good Research Practices – budget Impact Analysis. Value Health. 2014;17:5–14.
   PubMed Web of Science ®Google Scholar
• Mauskopf JA, Earnshaw S, Mullins CD. Budget impact analysis: review of the state of the art. Expert Rev Pharmacoecon Outcomes Res. 2005 Feb 5;5(1):65–79.
   PubMedGoogle Scholar
• Marshall DA, Douglas PR, Drummond MF, et al. Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada. PharmacoEconomics. 2008;26(6):477–495.
   PubMed Web of Science ®Google Scholar
• Orlewska E, Gulácsi L. Budget-impact analyses: a critical review of published studies. PharmacoEconomics. 2009;27(10):807–827.
   PubMed Web of Science ®Google Scholar
• Garattini L, Van De Vooren K. Budget impact analysis in economic evaluation: a proposal for a clearer definition. Eur J Health Econ. 2011;12:499–502.
   PubMed Web of Science ®Google Scholar
• Nuijten M, Mittendorf T, Persson U. Practical issues in handling data input and uncertainty in a budget impact analysis. Eur J Health Econ. 2011;12:231–241.
   PubMed Web of Science ®Google Scholar
• Brazil. Ministry of Health. Secretariat of Science, Technology and Strategic Inputs. Department of Science and Technology. Methodological guidelines: budget impact: analysis guidelines for the Brazilian health system. Brazil; Ministry of Health; set. Livrotab. (A: Regulatory and Technical Manuals). 2012. [cited 2020 Jan 4]. Available from: https://portalarquivos2.saude.gov.br/images/pdf/2014/novembro/10/Diretrizes-metodologicas-manual-de-analise-de-impacto-orcamentario-cienciasus.pdf
   Google Scholar
• Ferreira-Da-Silva AL, Ribeiro RA, Santos VCC, et al. Guidelines for budget impact analysis of health technologies in Brazil. Cad Saúde Pública. 2012 jul;28(7):1223–1238. Rio de Janeiro.
   PubMed Web of Science ®Google Scholar
• Van De Vooren K, Duranti S, Curto A, et al. A critical systematic review of budget impact analyses on drugs in the EU countries. Appl Health Econ Health Policy. 2014 Feb;12(1):33–40.
   PubMedGoogle Scholar
• Faleiros DR, Álvares J, Almeida AM, et al. Budget impact analysis of medicines: updated systematic review and implications. Expert Rev Pharmacoecon Outcomes Res. 2016;16(2):257–266. Epub (2016).
   PubMed Web of Science ®Google Scholar
• Mauskopf J, Earnshaw S. Methodological review of US budget-impact models for new drugs. PharmacoEconomics. 2016 June 22;34:1111–1131. [Epub ahead of print]. PMID: 27334107.
   PubMed Web of Science ®Google Scholar
• Lamrock F, McCullagh L, Tilson L, et al. *A retrospective analysis of budget impact models submitted to the National Centre for Pharmacoeconomics in Ireland. Eur J Health Econ. 2020 Aug;21(6):895–901. Epub 2020 March 30. PMID: 32232603; PMCID: PMC7366580.
   PubMed Web of Science ®Google Scholar
• Malmström RE, Godman BB, Diogene E, et al. A case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol. 2013;4:39.
   PubMed Web of Science ®Google Scholar
• Joppi R, Cinconze E, Mezzalira L, et al. Italian Horizon Scanning Project. Hospitalized patients with atrial fibrillation compared to those included in recent trials on novel oral anticoagulants: a population-based study. Eur J Intern Med. 2013 Jun;24(4):318–323.
   PubMed Web of Science ®Google Scholar
• FDA. FDA approves larotrectinib for solid tumors with NTRK gene fusions. 2018. [cited 2019 May 23]. Available from: https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions-0
   Google Scholar
• Pontes C, Zara C, Torrent-Farnell J, et al. Time to review authorisation and funding for new cancer medicines in Europe? Inferences from the case of Olaratumab. Appl Health Econ Health Policy. 2020 Feb;18(1):5–16.
   PubMed Web of Science ®Google Scholar
• Zampirolli Dias C, Godman B, Gargano LP, et al. Integrative Review of managed entry agreements: chances and limitations. Pharmacoeconomics. 2020 Nov;38(11):1165–1185.
   PubMed Web of Science ®Google Scholar
• Eriksson I, Wettermark B, Bergfeldt K. Real-World use and outcomes of olaparib: a population-based cohort study. Target Oncol. 2018 Dec;13(6):725–733.
   PubMed Web of Science ®Google Scholar
• Brazil. Ministry of Health. Secretariat of Science, Technology and Strategic Inputs. Ordinance No. 66 of November 6, 2006. Approves the Clinical Protocol and Therapeutic Guidelines - Rheumatoid Arthritis. Diário Oficial [da] União, Executive Branch, Brasília, DF. 2006 Nov 6. Accessed 22 May 2020. Available from: http://bvsms.saude.gov.br/bvs/saudelegis/sctie/2006/prt0066_01_11_2006_comp.html
   Google Scholar
• Marques Neto JF, Gonçalves ET, Langen LFOB, et al. [Multicenter study of the prevalence of adult rheumatoid arthritis in people of the Brazilian population]. Rev Bras Reumatol. 1993;33:169–173. Available in print
   Google Scholar
• Carias CM, Vieira FS, Giordano CV, et al. Exceptional circumstance drug dispensing: history and expenditures of the Brazilian Ministry of Health. Rev Saúde Pública. 2011;45:233–240.
   PubMed Web of Science ®Google Scholar
• Ghabri S, Mauskopf J. The use of budget impact analysis in the economic evaluation of new medicines in Australia, England, France and the United States: relationship to cost‑effectiveness analysis and methodological challenges. Eur J Health Econ. 2017;19:173–175.
   PubMed Web of Science ®Google Scholar
• Foroutan N, Tarride JE, Xie F, et al. ** A methodological review of national and transnational pharmaceutical budget impact analysis guidelines for new drug submissions. Clinicoecon Outcomes Res. 2018;10:821‐854. Published 2018 Nov 26
   PubMed Web of Science ®Google Scholar
• Paim J, Travassos C, Almeida C, et al. The Brazilian health system: history, advances, and challenges. Lancet. 2011;377:1778–1797. Published Online.
   PubMed Web of Science ®Google Scholar
• Brazil. Ministry of Health. Office of the Minister. Ordinance No. 152 of January 19, 2006. Institutes the flow for incorporation of technologies within the scope of the Unified Health System. Diário Oficial [da] União, Executive Branch, Brasília, DF. 2006 Jan 21. [cited 2019 Feb 11]. Available from: http://bvsms.saude.gov.br/bvs/saudelegis/gm/2006/prt0152_19_01_2006_comp.html
   Google Scholar
• Brazil. Ministry of Health. Office of the Minister. Ordinance No. 3,323 of December 27, 2006. Institutes the commission for the incorporation of technologies within the scope of the Unified Health System and Supplementary Health. Diário Oficial [da] União, Executive Branch, Brasília, DF. 2006 Dec 27. [cited 2020 May 21]. Available from: http://bvsms.saude.gov.br/bvs/saudelegis/gm/2006/prt3323_27_12_2006_comp.html
   Google Scholar
• Brazil. Law No. 12,401, of April 28, 2011. Amends Law No. 8,080, of September 19, 1990, to provide for therapeutic assistance and the incorporation of health technology within the scope of the Unified Health System - SUS. Diário Oficial [da] União, Executive Branch, Brasília, DF. 2002 Sept 20. [citeed 2019 Dec 2]. Available from: https://www2.camara.leg.br/legin/fed/lei/2011/lei-12401-28-abril-2011-610586-veto-132351-pl.html
   Google Scholar
• Brazil. Decree No. 7,646, of December 21, 2011. Provides for the National Commission for the Incorporation of Technologies in the Unified Health System and the administrative process for incorporation, exclusion and alteration of health technologies by the Unified Health System - SUS, and gives other measures. Diário Oficial [da] União, Executive Branch, Brasília, DF, 2002 Dec 22. [cited 2020 Dec 22]. Available from: http://www.planalto.gov.br/CCIVIL_03/_Ato2011-2014/2011/Decreto/D7646.htm#:~:text=Disp%C3%B5e%20sobre%20a%20Comiss%C3%A3o%20Nacional,SUS%2C%20e%20d%C3%A1%20outras%20provid%C3%AAncias
   Google Scholar
• Brazil. Ministry of Health. Office of the Minister. Ordinance No. 1,555, of July 30, 2013. Provides for the rules on financing and execution of the Specialized Component of Pharmaceutical Assistance within the scope of the Unified Health System (SUS). Diário Oficial [da] União. Brasília. 2013 Jul 31. [cited 2020 Feb 8]. Available from: http://bvsms.saude.gov.br/bvs/saudelegis/gm/2013/prt1555_30_07_2013.html
   Google Scholar
• Caires De Souza AL, De Assis Acurcio F, Guerra Júnior AA, et al. Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review. Appl Health Econ Health Policy. 2014 Feb;12(1):19–32.
   PubMedGoogle Scholar
• Marra LP, Araújo VE, Oliveira GC, et al. The clinical effectiveness of insulin glargine in patients with Type I diabetes in Brazil: findings and implications. J Comp Eff Res. 2017 Sep;6(6):519–527.
   PubMed Web of Science ®Google Scholar
• Almeida PHRF, Silva TBC, De Assis Acurcio F, et al. Quality of life of patients with type 1 diabetes mellitus using insulin analog glargine compared with NPH Insulin: a systematic review and policy implications. Patient - Patient-Centered Outcomes Res. 2018 Aug;11(4):377–389.
   Web of Science ®Google Scholar
• Brazil. Ministry of Health. Legal Consulting. [Judicial intervention in public health: overview in the scope of Federal Justice and notes in the field of State Justice]. 2012. [cited 2019 Oct 6]. Available from: http://u.saude.gov.br/images/pdf/2014/maio/29/Panorama-da-judicializa—-o—2012—modificado-em-junho-de-2013.pdf
   Google Scholar
• Falconetti MFPV, Nascimento EB [The use of adalimumab and etanercept for rheumatoid arthritis in SUS: therapeutic efficacy or judicial pressure?] Júnior Pós em revista do centro universitário Newton Paiva 1/2012 - EDIÇÃO 5 - 2176 7785. [cited 2018 May 13]. Available from: https://posemrevista.files.wordpress.com/2012/06/pdf-e5-s34.pdf
   Google Scholar
• Brazil. Ministry of health. Health Care Secretariat. Ordinance SAS/MS No. 865, of November 5, 2002. Approves the Clinical Protocol and therapeutic guidelines - Rheumatoid Arthritis. Diário Oficial [da] União, Executive Branch, Brasília, DF. 2002 Nov 6. Available in print.
   Google Scholar
• Brazil. Ministry of Health. Brazilian Health Technology Assessment Network - REBRATS. Brazilian Health Technology Budget Impact Worksheet. Complementary Instruments. Complementary instruments. Archive. Version developed for Pharmaceuticals - January 2011. [cited 2018 Dec 5]. Available from: http://rebrats.saude.gov.br/instrumentos-complementares?download=115:planilha-brasileira-para-analise-do-impacto-orcamentario-de-dispositivos-terapeuticos-excel
   Google Scholar
• Cowen and Company. Therapeutic Categories outlook (report). 2009. Available from: https://pt.scribd.com/doc/103607058/Cowen-Therapeutic-Outlook-March-2009
   Google Scholar
• Jonsson B, Kobelt G, Smolen J. The burden of rheumatoid arthritis and access to treatment: uptake of new therapies. Eur J Health Econ. 2008;8(Suppl 2):S61–S86.
   PubMed Web of Science ®Google Scholar
• Costa JO, Almeida AM, Guerra Junior AA, et al. Treatment of rheumatoid arthritis in the Brazilian Unified National Health System: expenditures on infliximab compared to synthetic disease-modifying anti-rheumatic drugs, 2003-2006. Cad Saúde Pública. 2014;30(2):283–295. Rio de Janeiro.
   PubMed Web of Science ®Google Scholar
• Silva GD [Cost-utility assessment of the treatment of Rheumatoid Arthritis offered at SUS-MG]. Advisor: francisco de Assis Acurcio. 2016. 211 f. [Thesis (Doctorate in Public Health)]. Belo Horizonte: Faculty of Medicine, Federal University of Minas Gerais; 2016. Available in print.
   Google Scholar
• BRAZIL. Brazilian Institute of Geography and Statistics (IBGE). Population Brazil 2000 - 2015. [cited 2018 Dec 13]. Available from: www.ibge.gov.br
   Google Scholar
• Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy to treat rheumatoid arthritis: outcomes of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003 Dec;30(12):2563–2571. PMID: 14719195. Available from. https://www.jrheum.org/content/jrheum/30/12/2563.full.pdf
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48(1):35–45.
   PubMed Web of Science ®Google Scholar
• Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with Adalimumab (a human antitumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52week trial. Arthritis Rheum. 2004;50(5):1400–1411.
   PubMed Web of Science ®Google Scholar
• Van De Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of Adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease-modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63(5):508–516.
   PubMed Web of Science ®Google Scholar
• Gomes RKS, Pires FA, Nobre MRC, et al. Impact of rheumatoid arthritis in the public health system in Santa Catarina, Brazil: a descriptive and temporal trend analysis in the period from 1996 to 2009. Rev Bras Reumatol. 2016. DOI:10.1016/j.rbre.2016.07.003.
   Google Scholar
• Guerra JAA, Acurcio FA, Gomes GAP, et al. Availability of essential drugs in two regions of Minas Gerais, Brazil. Rev Panam Salud Publica. 2004;15(3):168–175. Available from.
   PubMed Web of Science ®Google Scholar
• Tasca RS, Soares DA, Cuman RKN. Access to antihypertensive drugs in a basic health unit in maringá – paraná. Arq Ciênc Saúde Unipar. 1999;3(2):117–124.
   Google Scholar
• Chaves GC, Emmerick I, Pouvourville N, et al. [Indicators of rational use of medicines and access to medicines: a case article]. Rev Bras Farm. 2005;86(3):97–103. Available from: https://www.scielo.br/pdf/rsp/v51s2/pt_0034-8910-rsp-S1518-51-s2-87872017051007139.pdf
   Google Scholar
• Pan American Health Organization/World Health Organization; Ministry of Health. Evaluation of pharmaceutical assistance in Brazil. Medicines and other essential health supplies series. Brazil, DF. Ministério da Saúde; 2005. [cited 2019 Oct 12]. Available from: http://bvsms.saude.gov.br/bvs/publicacoes/avaliacao_assistencia_farmaceutica_estrutura_resultados.pdf
   Google Scholar
• Brazil. Ministry of health. Executive secretariat. health information notebook: primary care indicators. [cited 2019 May 22]. Available from: http://datasus.saude.gov.br
   Google Scholar
• Baumgart DC, Misery L, Naeyaert S, et al. Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities? Front Pharmacol. 2019;10:279. Published 2019 Mar 28.
   PubMed Web of Science ®Google Scholar
• Putrik P, Ramiro S, Kvien TK, et al. Working Group ‘Equity in access to treatment of rheumatoid arthritis in Europe’. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014 Jan;73(1):198–206.
   PubMed Web of Science ®Google Scholar
• Kostić M, Djakovic L, Šujić R, et al. Inflammatory bowel diseases (crohn´s disease and ulcerative colitis): cost of treatment in serbia and the implications. Appl Health Econ Health Policy. 2017;15(1):85–93.
   PubMed Web of Science ®Google Scholar
• Brazil. Ministry of Health. executive secretariat. department of health economics, investments and development. health price bank (BPS) - BPS of the ministry of health. Ministério da Saúde. 2018 [cited 2019 May 22]. Available from: http://bps.saude.gov.br/login.jsf
   Google Scholar
• DRUGDEX® Drug Point. Infliximab. MICROMEDEX® healthcare series 2006. [cited 2018 Dec 2]. Available from: http://www.thomsonhc.com
   Google Scholar
• DRUGDEX® Drug Point. Adalimumab. MICROMEDEX ® healthcare series 2006.  [cited 2018 Dec 2]. Available from: http://www.thomsonhc.com
   Google Scholar
• DRUGDEX® Drug Point. Etanercept. MICROMEDEX® healthcare series 2006. [cited 2018 Dec 2]. Available from: http://www.thomsonhc.com
   Google Scholar
• Cherchiglia ML, Guerra AA Jr, Andrade EIG, et al. [The construction of the national database on renal replacement therapy (RRT) centered on the individual: application of the deterministic-probabilistic linkage method]. Rev Bras Estud Popul. 2007;24:163–167.
   Google Scholar
• Queiroz OV, Guerra AA Jr, Machado CJ, et al. *Record linkage of large data sources: parameter estimation and results validation, applied to the linkage of high complexity procedures authorizations with the hospital information system. Cad Saúde Colet. 18(2):298–308. [cited 2019 Dec 5]. Available from: http://www.cadernos.iesc.ufrj.br/cadernos/images/csc/2010_2/artigos/CSCv18n2_298-308.pdf
   Google Scholar
• Acurcio FA, Cmr B, Guerra AA Jr, et al. Epidemiological profile of high cost medicines users in the Brazilian Health System. Rev Bras Estud Popul. 2009;26:263.42.
   Google Scholar
• Guerra AA Jr, AcUrcioI FA, Andrade EIG, et al. Cyclosporine versus tacrolimus in kidney transplants in Brazil: a cost comparison. Cad Saude Publica. 2010;26(1):163.
   PubMed Web of Science ®Google Scholar
• Gomes RM, Guerra Júnior AA, Lemos LL, et al. Ten-year kidney transplant survival of cyclosporine- or tacrolimus-treated patients in Brazil. Expert Rev Clin Pharmacol. 2016 Jul;9(7):991–999.
   PubMed Web of Science ®Google Scholar
• Barbosa WB, Costa JO, De Lemos LLP, et al. Costs in the treatment of schizophrenia in adults receiving atypical antipsychotics: an 11-year cohort in Brazil. Appl Health Econ Health Policy. 2018;16(5):697–709.
   PubMed Web of Science ®Google Scholar
• Barbosa WB, Gomes RM, Godman B, et al. Real-world effectiveness of olanzapine and risperidone in the treatment of schizophrenia in Brazil over a 16-year follow-up period; findings and implications. Expert Rev Clin Pharmacol. 2020;1–11. DOI:10.1080/17512433.2021.1865799.
   Web of Science ®Google Scholar
• Garcia MM, Barbosa WB, Barbosa MM, et al. *Survey of values of acquisition of medicines of the Specialized Component of Pharmaceutical Assistance in Brazil - Report number: 01/2018 – [Survey of drug acquisition values of the Specialized Component of Pharmaceutical Assistance in Brazil]. 2018.
   Google Scholar
• The World Bank. PPP conversion factor. [cited 2020 May 2]. Available from: https://data.worldbank.org/indicator/PA.NUS.PPP
   Google Scholar
• Snider JT, Sussell J, Tebeka MG, et al. Challenges with Forecasting Budget Impact: a Case Study of Six ICER Reports. Value Health. 2018 Mar;22(3):332–339. Epub 2018 Dec 14. PMID: 30832971.
   PubMed Web of Science ®Google Scholar
• Matusewicz W, Godman B, Pedersen HB, et al. Improving the managed introduction of new medicines: sharing experiences to aid authorities across Europe. Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):755–758.
   PubMed Web of Science ®Google Scholar
• Nascimento RCRM, Álvares J, Guerra Junior AA, et al. Availability of essential medicines in primary health care of the Brazilian Unified Health System. Rev Saude Publica. 2017;51(Suppl 2):10s.
   PubMedGoogle Scholar
• Geenen JW, Boersma C, Klungel OH, et al. **Accuracy of budget impact estimations and impact on patient access: a hepatitis C case study. Eur J Health Econ. 2019;20:857–867.
   PubMed Web of Science ®Google Scholar
• Keeping S, Deslandes PN, Haines KE, et al. *Estimated versus observed expenditure associated with medicines recommended by the all wales medicines strategy group. PharmacoEconomics Open. 2019;3(3):343–350.
   PubMed Web of Science ®Google Scholar
• Broder MS, Zambrano JM, Lee J, et al. *Systematic BIAs in predictions of new drugs’ budget impact: analysis of a sample of recent US drug launches. Curr Med Res Opin. 2018 May;34(5):765–773. Epub 2017 May 3. PMID: 28418263.
   PubMed Web of Science ®Google Scholar
• Iwanczuk T, Zawodnik S, Tatara T, et al. *Reliability of manufacturers’ budget impact estimates for chronic Hcv Gt1 drugs in Poland. November 2015. Value Health. 2015;18(7):A595.
   Web of Science ®Google Scholar
• Cha M, Rifai B, Sarraf P. *Pharmaceutical forecasting: throwing darts? Nat Rev Drug Discov. 2013 Oct;12(10):737–738. PMID: 24080692. (2103).
   PubMed Web of Science ®Google Scholar
• Sooksriwong C, Chanjaruporn F. *Budget impact analysis: a difference between theory and practice. Mahidol Univ J Pharm Sci. 2011;38(3–4):34–40. Available from: https://pharmacy.mahidol.ac.th/journal/_files/2011-38-2_34-40.pdf
   Google Scholar
• Eriksson I, Wettermark B, Persson M, et al. The early awareness and alert system in sweden: history and current status. Front Pharmacol. 2017;8:674.
   PubMed Web of Science ®Google Scholar
• Eriksson I, Von Euler M, Malmström RE, et al. Did we see it Coming? An evaluation of the swedish early awareness and alert system. Appl Health Econ Health Policy. 2019 Feb;17(1):93–101.
   PubMed Web of Science ®Google Scholar
• Frisk P, Aggefors K, Cars T, et al. Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden. Eur J Clin Pharmacol. 2018 Jul;74(7):971–978.
   PubMed Web of Science ®Google Scholar
• Wettermark B, Persson ME, Wilking N, et al. Regional Drug Expert Consortium in Stockholm County Council. Forecasting drug utilization and expenditure in a metropolitan health region. BMC Health Serv Res. 2010;10:128.
   PubMed Web of Science ®Google Scholar